Study of Advanced Therapies for the Treatment of Adult Participants With Moderately to Severely Active Crohn's Disease or Ulcerative Colitis

Conditions

• Crohn's Disease
• Ulcerative Colitis

Eligibility Criteria

Sex

ALL

Age

18 Years - 75 Years

Healthy Volunteers

Not accepted

Interventions

• Risankizumab — DRUG
  Intravenous/Subcutaneous/Intramuscular Injection/Infusion
• Trosunilimab — DRUG
  Intravenous/Subcutaneous/Intramuscular Injection/Infusion
• ABBV-701 — DRUG
  Intravenous/Subcutaneous/Intramuscular Injection/Infusion

Study Details

Crohn's disease (CD) and Ulcerative colitis (UC) are 2 types of inflammatory bowel diseases which cause long-lasting, severe inflammation (redness, swelling) in the digestive tract. CD can affect any part of the digestive tract causing many different symptoms including belly pain, diarrhea, tiredness, and weight loss. UC affects the lining of the rectum and colon (large intestine) and can cause bleeding, belly pain, and diarrhea. This platform basket study will evaluate how safe and effective advanced therapies are in adults with moderately to severely active Crohn's Disease (CD) or Ulcerative Colitis (UC). This study currently includes 2 substudies evaluating different treatments in participants with CD or UC. Substudy 1 will evaluate the combination of risankizumab and trosunilimab (ABBV-466) and Substudy 2 will evaluate the combination of risankizumab and ABBV-701 (ABBV-7066). When adult participants with moderately to severely active CD or UC join the study, they will undergo a 2-step randomization within CD and UC substudies, respectively. The first unblinded randomization will assign participants into a substudy, and the second blinded randomization will assign participants to a treatment arm within the assigned substudy. Approximately 100 adult participants will be enrolled per treatment arm across both substudies at approximately 400 sites worldwide. There may be higher treatment burden for participants in this trial compared to their standard of care treatment without participating in this study. Participants will attend regular visits during the study at a hospital or clinic. The effect of the treatment will be checked by medical assessments, blood tests, stool tests, endoscopies, checking for side effects and completing questionnaires and a daily diary.

Key Dates

First listed

Jul 13, 2026

Start date

Jul 31, 2026

Status verified

Sep 2026

Primary completion

Oct 31, 2031

Completion

Oct 31, 2031

Study Design

Enrollment

2,000 participants (estimated)

Allocation

RANDOMIZED

Intervention model

PARALLEL

Primary purpose

TREATMENT

Arms

• Experimental: Substudy 1: UC Arm 1 Risankizumab monotherapy
  Ulcerative Colitis (UC) participants will receive Risankizumab Dose A as induction treatment followed by Risankizumab Dose C as maintenance treatment.
• Experimental: Substudy 1: CD Arm 1 Risankizumab monotherapy
  Crohn's Disease (CD) participants will receive Risankizumab Dose B as induction treatment followed by Risankizumab Dose D as maintenance treatment.
• Experimental: Substudy 1: UC Arm 2 Trosunilimab monotherapy
  Ulcerative Colitis (UC) participants will receive Trosunilimab Dose A as induction treatment followed by Trosunilimab Dose C as maintenance treatment.
• Experimental: Substudy 1: CD Arm 2 Trosunilimab monotherapy
  Crohn's Disease (CD) participants will receive Trosunilimab Dose B as induction treatment followed by Trosunilimab Dose D as maintenance treatment.
• Experimental: Substudy 1: UC Arm 3 Trosunilimab monotherapy
  Ulcerative Colitis (UC) participants will receive Trosunilimab Dose E as induction treatment followed by Trosunilimab Dose G as maintenance treatment.
• Experimental: Substudy 1: CD Arm 3 Trosunilimab monotherapy
  Crohn's Disease (CD) participants will receive Trosunilimab Dose F as induction treatment followed by Trosunilimab Dose H as maintenance treatment.
• Experimental: Substudy 1: UC Arm 4 ABBV-466 (Risankizumab/Trosunilimab)
  Ulcerative Colitis (UC) participants will receive a combination induction treatment of ABBV-466 (Risankizumab/Trosunilimab) combo Dose A followed by a combination maintenance (Risankizumab/Trosunilimab) combo Dose C
• Experimental: Substudy 1: CD Arm 4 ABBV-466 (Risankizumab/Trosunilimab)
  Crohn's Disease (CD) participants will receive a combination induction treatment of ABBV-466 (Risankizumab/Trosunilimab) combo Dose B followed by a combination maintenance (Risankizumab/Trosunilimab) combo Dose D
• Experimental: Substudy 1: UC Arm 5 ABBV-466 (Risankizumab/Trosunilimab)
  Ulcerative Colitis (UC) participants will receive a combination induction treatment of ABBV-466 (Risankizumab/Trosunilimab) combo Dose E followed by a combination maintenance (Risankizumab/Trosunilimab) combo Dose G
• Experimental: Substudy 1: CD Arm 5 ABBV-466 (Risankizumab/Trosunilimab)
  Crohn's Disease (CD) participants will receive a combination induction treatment of ABBV-466 (Risankizumab/Trosunilimab) combo Dose F followed by a combination maintenance (Risankizumab/Trosunilimab) combo Dose H
• Experimental: Substudy 2: UC Arm 1 Risankizumab monotherapy
  Ulcerative Colitis (UC) participants will receive Risankizumab Dose A as induction treatment followed by Risankizumab Dose C as maintenance treatment.
• Experimental: Substudy 2: CD Arm 1 Risankizumab monotherapy
  Crohn's Disease (CD) participants will receive Risankizumab Dose B as induction treatment followed by Risankizumab Dose D as maintenance treatment.
• Experimental: Substudy 2: UC Arm 2 ABBV-701 monotherapy
  Ulcerative Colitis (UC) participants will receive ABBV-701 Dose A as induction treatment and Dose C maintenance treatment.
• Experimental: Substudy 2: CD Arm 2 ABBV-701 monotherapy
  Crohn's Disease (CD) participants will receive ABBV-701 Dose B as induction treatment and Dose D maintenance treatment.
• Experimental: Substudy 2: UC Arm 3 ABBV-701 monotherapy
  Ulcerative Colitis (UC) participants will receive ABBV-701 Dose E as induction treatment and Dose G maintenance treatment.
• Experimental: Substudy 2: CD Arm 3 ABBV-701 monotherapy
  Crohn's Disease (CD) participants will receive ABBV-701 Dose F as induction treatment and Dose H maintenance treatment.
• Experimental: Substudy 2: UC Arm 4 ABBV-7066 (Risankizumab/ABBV-701)
  Ulcerative Colitis (UC) participants will receive induction treatment of ABBV-7066 (Risankizumab/ABBV-701) combination Dose A followed by maintenance treatment of ABBV-7066 (Risankizumab/ABBV-701) combination Dose C.
• Experimental: Substudy 2: CD Arm 4 ABBV-7066 (Risankizumab/ABBV-701)
  Crohn's Disease (CD) participants will receive induction treatment of ABBV-7066 (Risankizumab/ABBV-701) combination Dose B followed by maintenance treatment of ABBV-7066 (Risankizumab/ABBV-701) combination Dose D.
• Experimental: Substudy 2: UC Arm 5 ABBV-7066 (Risankizumab/ABBV-701)
  Ulcerative Colitis (UC) participants will receive induction treatment of ABBV-7066 (Risankizumab/ABBV-701) combination Dose E followed by maintenance treatment of ABBV-7066 (Risankizumab/ABBV-701) combination Dose G.
• Experimental: Substudy 2: CD Arm 5 ABBV-7066 (Risankizumab/ABBV-701)
  Crohn's Disease (CD) participants will receive induction treatment of ABBV-7066 (Risankizumab/ABBV-701) combination Dose F followed by maintenance treatment of ABBV-7066 (Risankizumab/ABBV-701) combination Dose H.
• Experimental: Substudy 2: UC Arm 6 ABBV-7066 (Risankizumab/ABBV-701)
  Ulcerative Colitis (UC) participants will receive induction treatment of ABBV-7066 (Risankizumab/ABBV-701) combination Dose I followed by maintenance treatment of ABBV-7066 (Risankizumab/ABBV-701) combination Dose J
• Experimental: Substudy 2: CD Arm 6 ABBV-7066 (Risankizumab/ABBV-701)
  Crohn's Disease (CD) participants will receive induction treatment of ABBV-7066 (Risankizumab/ ABBV-701) combination Dose K followed by maintenance treatment of ABBV-7066 (Risankizumab/ ABBV-701) combination Dose L

Primary Outcome Measure

Crohn's Disease Specific: Percentage of Participants Achieving Endoscopic Remission [ Time Frame: At Week 28 ]

Central Contacts

• ABBVIE CALL CENTER
  844-663-3742
  [email protected]

Locations (41)

Find similar trials in Dothan, AL

Related Studies

• Improving the Quality of Care for Adults With Inflammatory Bowel Disease
  Enrolling By Invitation · Dartmouth-Hitchcock Medical Center · Los Angeles, California
• Study of the Kono-S Anastomosis Versus the Side-to-side Functional End Anastomosis
  Recruiting · Weill Medical College of Cornell University · New York, New York
• The Influence of a Fasting Mimicking Diet on Ulcerative Colitis
  Recruiting · Stanford University · Palo Alto, California
• Testing an Immunotherapy Anti-cancer Drug, Nivolumab, for Advanced Cancers in Patients With Autoimmune Disorders, AIM-NIVO
  PHASE1 · Recruiting · National Cancer Institute (NCI) · Sacramento, California